Vizgen, Inc., a life sciences company advancing spatial multi-omics, announced a strategic partnership with Hamamatsu Photonics K.K., a global leader in optical imaging technology. The collaboration integrates Hamamatsu's MoxiePlex™ multiplex immunofluorescence (mIF) imaging system with Vizgen's pathology-grade reagent and assay portfolio, delivering an end-to-end solution designed to bring multiplexed biomarker detection into translational and clinical research applications.
Addressing Workflow Barriers in Multiplex Assay Development
The partnership aims to eliminate common barriers in multiplex assay development by streamlining validation, simplifying workflow integration, and enabling researchers to focus on acquiring high-fidelity biological insights. By combining cutting-edge imaging with highly adaptable multiplex assays, the collaboration offers a joint solution designed to scale with customer needs and facilitate the transition from research to clinical impact.
"Partnerships like this are essential to push the field of multiplex immunofluorescence forward and bring advanced imaging technologies closer to clinical relevance," said Toshimichi Ishizuka, Director of the Systems Division at Hamamatsu Photonics. "By integrating our hardware with Ultivue's versatile chemistry, we're offering a solution that's not only powerful but practical for real-world use."
Technical Capabilities and Platform Integration
The MoxiePlex™ platform offers up to 9-color imaging with high throughput capacity of up to 60 slides per run, designed specifically for high-volume laboratories. Vizgen's InSituPlex® assays enable rapid deployment of custom research panels with pre-validated biomarkers, minimizing time-to-data while maintaining exceptional specificity and reproducibility. Together, these technologies empower research laboratories to build and refine multiplex assays with greater speed and confidence.
The companies plan to combine their expertise through validated InSituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multi-site deployments for translational research and clinical research applications.
Initial Focus on Non-Small Cell Lung Cancer Research
Among the first use cases for this integrated solution is the deployment of multiplex immunofluorescence panels for clinically relevant research on non-small cell lung cancer (NSCLC) specimens. This application demonstrates the partnership's commitment to addressing critical areas in oncology research where spatial biology insights can drive therapeutic advancement.
Rob Carson, Chief Executive Officer at Vizgen, said, "Our partnership with Hamamatsu brings together two technology leaders with the same, shared vision for impact in translational research and beyond. Through uniting competencies in automated imaging and protein assay engineering, we can deliver sample-to-answer insights and together serve more customers in their science."
Expanding Spatial Biology Applications
Vizgen operates at the forefront of spatial biology and multi-omics innovation through its pioneering MERFISH technology and MERSCOPE® Platform for in situ single-cell spatial genomics, along with its high-fidelity InSituPlex® protein assays and AI-driven STARVUE™ spatial image analysis technology. These tools enable researchers to uncover deep insights into human biology and achieve breakthroughs in understanding mechanisms of complex diseases, including neurodegenerative disorders and cancer.
Hamamatsu Photonics' MoxiePlex™ system represents a 9-color multiplex immunofluorescence imaging platform designed to advance spatial proteomics from research to the clinic, starting with immuno-oncology and expanding into broader translational pathology applications. Both the InSituPlex® and MoxiePlex systems are designated for research use only.
